Mendoza-Álvarez SA, Moranchel-García L, Rodríguez-Corchado BG, Deras-Quiñones A

Language: Spanish
References: 19
Page: 1000-1006
PDF size: 432.40 Kb.

ABSTRACT

This paper reports the case of a 55 year-old man who presented with fever as a primary symptom of his condition. A systematic protocol oriented study led to the diagnosis of fever of unknown origin as a syndrome whose etiologic diagnosis was primary myelofibrosis; rare hematologic disease characterized by fibrosis of the bone marrow, anemia and splenomegaly. A review of the approach of fever and stages of study is done according to current recommendations, technical and scientific, but adapted to our environment and resources.

REFERENCES

1. Romo J, Muñoz J. Protocolo diagnóstico en fiebre de origen desconocido para países en vías de desarrollo. Anales de la Facultad de Medicina 2004;65(2):127-132.

2. Cervantes F, Barosi G, Demory JL, et al. Myelofibrosis with myeloid metaplasia in young individuals disease characteristics prognostic factor and identification of risk groups. Br J Haematol 1998;102;684-90.

3. Petersdorf RO, Beeson PB. Fever of unexplained origin: Report on 100 cases. Medicine (Baltimore) 1961;40:1-30.

4. Casarrubias-Ramírez M, Alfaro-Mejía JA, De Santiago- Leaños J, et al. Fiebre de origen oscuro, comparación de dos series con 26 años de diferencia. Rev Med Inst Mex Seguro Soc 2015;53(Supl 1):S6-17.

5. Durack DT, Street AC. Fever of unknown origin-reexamined and redefined. En: Remington JS, Swartz MN, editors. Current Clinical Topics in Infectious Diseases, volume 11. Boston: Blackwell; 1991;35-51.

6. Knockaert DC, Vanderschueren S, Blockmans D. Fever of unknown origin in adults: 40 years on. J Intern Med 2003;253:263-75.

7. Salzberger B, Müller-Schilling M, Fleck M. Fever of unknown origin. Z Rheumatol 2013 Apr;72(3):255-66.

8. Tefferi A: Myelofibrosis with myeloid metaplasia. N Engl J Med 2000;342(17):1255-65.

9. Agarwal A, Morrone K, Bartenstein M, Zhao ZJ, Verma A, Goel S. Bone marrow fibrosis in primary myelofibrosis: pathogenic mechanisms and the role of TGF-β. Stem Cell Investig 2016 Feb 26;3:5.

10. Tam CS, Kantarjian H, Cortes J, et al. Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. J Clin Oncol 2009;27(33):5587-93.

11. Kadia TM. Personalized treatment for patients with myelofibrosis. Clin Adv Hematol Oncol 2016 Jun;14(6):400-403.

12. Chim CS, Kwong YL, Lie AK, et al. Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia. Arch Intern Med 2005;165(22):2651-8.

13. Tefferi A, Thiele J, Vardiman JW. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer 2009;115(17):3842-7.

14. Hennessy BT, Thomas DA, Giles FJ, et al. New approaches in the treatment of myelofibrosis. Cancer 2005;103(1):32-43.

15. Strasser-Weippl K, Steurer M, Kees M, et al. Age and hemoglobin level emerge as most important clinical prognostic parameters in patients with osteomyelofibrosis: introduction of a simplified prognostic score. Leuk Lymphoma. 2006;47(3):441-50.

16. Tefferi A, Lasho TL, Jimma T, et al. One thousand patients with primary myelofibrosis: the mayo clinic experience. Mayo Clin Proc 2012;87(1):25-33.

17. Hussein K, Pardanani AD, Van Dyke DL, et al. International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis. Blood 2010;115(3):496-9.

18. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009;113(13):2895-901.

19. Morel P, Duhamel A, Hivert B, et al. Identification during the follow-up of time-dependent prognostic factors for the competing risks of death and blast phase in primary myelofibrosis: a study of 172 patients. Blood 2010;115(22):4350-5.